Targeting ERK-MYD88 interaction leads to ERK dysregulation and immunogenic cancer cell death - Archive ouverte HAL
Journal Articles Nature Communications Year : 2024

Targeting ERK-MYD88 interaction leads to ERK dysregulation and immunogenic cancer cell death

Samir Merabet
Vincent Chaptal
N Aznar
Serge Manié
Toufic Renno

Abstract

The quest for targeted therapies is critical in the battle against cancer. The RAS/MAP kinase pathway is frequently implicated in neoplasia, with ERK playing a crucial role as the most distal kinase in the RAS signaling cascade. Our previous research demonstrated that the interaction between ERK and MYD88, an adaptor protein in innate immunity, is crucial for RAS-dependent transformation and cancer cell survival. In this study, we examine the biological consequences of disrupting the ERK-MYD88 interaction through the ERK D-recruitment site (DRS), while preserving ERK’s kinase activity. Our results indicate that EI-52, a small-molecule benzimidazole targeting ERK-MYD88 interaction induces an HRI-mediated integrated stress response (ISR), resulting in immunogenic apoptosis specific to cancer cells. Additionally, EI-52 exhibits anti-tumor efficacy in patient-derived tumors and induces an anti-tumor T cell response in mice in vivo. These findings suggest that inhibiting the ERK-MYD88 interaction may be a promising therapeutic approach in cancer treatment.
Fichier principal
Vignette du fichier
s41467-024-51275-z.pdf (3.14 Mo) Télécharger le fichier
Origin Publisher files allowed on an open archive

Dates and versions

hal-04676566 , version 1 (23-08-2024)

Identifiers

Cite

François Virard, Stéphane Giraud, Mélanie Bonnet, Léa Magadoux, Laetitia Martin, et al.. Targeting ERK-MYD88 interaction leads to ERK dysregulation and immunogenic cancer cell death. Nature Communications, 2024, 15, pp.7037. ⟨10.1038/s41467-024-51275-z⟩. ⟨hal-04676566⟩
117 View
18 Download

Altmetric

Share

More